[Immunosuppressive strategies and chronic graft dysfunction in kidney transplantation].

[1]  F. Cosio,et al.  Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  E. Thervet,et al.  Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6‐Month Course of Steroids , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  M. Arias,et al.  Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients. , 2007, Transplantation proceedings.

[4]  B. Nashan,et al.  Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  L. Rostaing,et al.  Impact of Cyclosporine Reduction With MMF: A Randomized Trial in Chronic Allograft Dysfunction. The ‘Reference’ Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  J. Grinyó,et al.  Mycophenolate Mofetil and Sirolimus Combination in Renal Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  M. Copin,et al.  Assessment of the Risk of Chronic Allograft Dysfunction after Renal Transplantation in a Randomized Cyclosporine Withdrawal Trial , 2006, Transplantation.

[8]  J. Chapman,et al.  Chronic Allograft Nephropathy: Current Concepts and Future Directions , 2006, Transplantation.

[9]  W. Weimar,et al.  Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  K. Natarajan,et al.  Costimulation blockade with belatacept in renal transplantation. , 2005, The New England journal of medicine.

[11]  M. Copin,et al.  Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. , 2005, Journal of the American Society of Nephrology : JASN.

[12]  D. Abramowicz,et al.  Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. , 2005, Journal of the American Society of Nephrology : JASN.

[13]  C. Dudley,et al.  Mycophenolate Mofetil Substitution for Cyclosporine A in Renal Transplant Recipients with Chronic Progressive Allograft Dysfunction: The “Creeping Creatinine” Study1 , 2005, Transplantation.

[14]  D. Goldsmith,et al.  Low-Dose Mycophenolate Mofetil is an Effective and Safe Treatment to Permit Phased Reduction in Calcineurin Inhibitors in Chronic Allograft Nephropathy , 2005, Transplantation.

[15]  G. Russ,et al.  Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[16]  J. Craig,et al.  A Randomized Controlled Trial of Cyclosporine Withdrawal in Renal-Transplant Recipients: 15-Year Results , 2004, Transplantation.

[17]  C. Ponticelli,et al.  Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study , 2004, Transplantation.

[18]  K. Shu,et al.  Sirolimus in chronic allograft nephropathy. , 2004, Transplantation proceedings.

[19]  J. Stoves,et al.  A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  K. Budde,et al.  Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  A. Gaber,et al.  COMPARISON OF SIROLIMUS-BASED CALCINEURIN INHIBITOR-SPARING AND CALCINEURIN INHIBITOR-FREE REGIMENS IN CADAVERIC RENAL TRANSPLANTATION , 2004, Transplantation.

[22]  B. Suwelack,et al.  Withdrawal of Cyclosporine or Tacrolimus After Addition of Mycophenolate Mofetil in Patients With Chronic Allograft Nephropathy , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  Julio Pascual,et al.  Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6‐Month Safety and Efficacy Results of Two Randomized Studies , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  J. D. de Fijter,et al.  Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. , 2003, Kidney international.

[25]  M. Nicholson,et al.  The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy , 2003, Transplantation.

[26]  D. Abramowicz,et al.  Cyclosporine withdrawal from a mycophenolate mofetil–containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study1,2 , 2002, Transplantation.

[27]  F. Schena,et al.  Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination1, 2 , 2002, Transplantation.

[28]  C. Billerey,et al.  Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up , 2002, Transplant international : official journal of the European Society for Organ Transplantation.

[29]  W. Weimar,et al.  Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. , 2002, Journal of the American Society of Nephrology : JASN.

[30]  J. D. de Fijter,et al.  Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. , 2002, Journal of the American Society of Nephrology : JASN.

[31]  R. Oberbauer,et al.  Sirolimus Allows Early Cyclosporine Withdrawal in Renal Transplantation Resulting in Improved Renal Function and Lower Blood Pressure. , 2001 .

[32]  J. Fink,et al.  Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. , 2001, Kidney international.

[33]  M. Mihatsch,et al.  Cyclosporine withdrawal in stable renal transplant recipients after azathioprine‐mycophenolate mofetil conversion , 2000, Clinical transplantation.

[34]  B. Kiberd,et al.  CONVERSION TO RAPAMYCIN IMMUNOSUPPRESSION IN RENAL TRANSPLANT RECIPIENTS: REPORT OF AN INITIAL EXPERIENCE1 , 2000, Transplantation.

[35]  T A Louis,et al.  A meta-analysis of immunosuppression withdrawal trials in renal transplantation. , 2000, Journal of the American Society of Nephrology : JASN.

[36]  M. Hazzan,et al.  Contribution of mycophenolate mofetil after withdrawal of cyclosporine to toxicity in kidney transplantation. , 1998, Transplantation proceedings.

[37]  P. Kuo,et al.  A novel approach to the treatment of chronic allograft nephropathy. , 1997, Transplantation.